SEC Form 4 · accession 0001209191-19-009655
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart A Arbuckle
Officer — EVP\Chief Commercial Officer
Period of report
Feb 11, 2019
Accepted (ET)
Feb 13, 2019 · 4:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Feb 11, 2019 | S | 10,657 | $179.44 | D | 61,280 | D | |
| Common StockF3,F4 | Feb 11, 2019 | S | 14,915 | $180.34 | D | 46,365 | D | |
| Common StockF3,F5 | Feb 11, 2019 | S | 7,501 | $181.03 | D | 38,864 | D | |
| Common Stock | holding | — | — | — | 140 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $179.44 (range $178.75 to $179.74).
- F3Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $180.34 (range $179.76 to $180.76).
- F5Open market sales reported on this line occurred at a weighted average price of $181.03 (range $180.77 to $181.59).